These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 23599757)
1. Polymorphisms in thymidylate synthase and reduced folate carrier ( Li WJ; Jiang H; Fang XJ; Ye HL; Liu MH; Liu YW; Chen Q; Zhang L; Zhang JY; Yuan CL; Zhang QY Oncol Lett; 2013 Apr; 5(4):1165-1170. PubMed ID: 23599757 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Takehara A; Kawakami K; Ohta N; Oyama K; Ota Y; Oda M; Watanabe G Anticancer Res; 2005; 25(6C):4455-61. PubMed ID: 16334126 [TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606 [TBL] [Abstract][Full Text] [Related]
4. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386 [TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate. Cwiklinska M; Czogala M; Kwiecinska K; Madetko-Talowska A; Szafarz M; Pawinska K; Wieczorek A; Klekawka T; Rej M; Stepien K; Halubiec P; Lazarczyk A; Miklusiak K; Bik-Multanowski M; Balwierz W; Skoczen S Front Pediatr; 2020; 8():307. PubMed ID: 32612964 [No Abstract] [Full Text] [Related]
8. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371 [TBL] [Abstract][Full Text] [Related]
9. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609 [TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. Arévalo E; Castañón E; López I; Salgado J; Collado V; Santisteban M; Rodríguez-Ruiz M; Martín P; Zubiri L; Patiño-García A; Rolfo C; Gil-Bazo I J Transl Med; 2014 Apr; 12():98. PubMed ID: 24726028 [TBL] [Abstract][Full Text] [Related]
11. [Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma]. Dong ZM; Cui YJ; Kuang G; Wang R; Yu FL; Zhang JH Ai Zheng; 2005 Oct; 24(10):1225-9. PubMed ID: 16219137 [TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480 [TBL] [Abstract][Full Text] [Related]
13. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Kawakami K; Graziano F; Watanabe G; Ruzzo A; Santini D; Catalano V; Bisonni R; Arduini F; Bearzi I; Cascinu S; Muretto P; Perrone G; Rabitti C; Giustini L; Tonini G; Pizzagalli F; Magnani M Clin Cancer Res; 2005 May; 11(10):3778-83. PubMed ID: 15897576 [TBL] [Abstract][Full Text] [Related]
14. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Hu Q; Li X; Su C; Chen X; Gao G; Zhang J; Zhao Y; Li J; Zhou C Exp Ther Med; 2012 Dec; 4(6):1010-1016. PubMed ID: 23226765 [TBL] [Abstract][Full Text] [Related]
15. Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Domingo P; Cabeza MC; Pruvost A; Torres F; Salazar J; del Mar Gutierrez M; Mateo MG; Fontanet A; Fernandez I; Domingo JC; Villarroya F; Vidal F; Baiget M Antimicrob Agents Chemother; 2011 Apr; 55(4):1428-35. PubMed ID: 21282454 [TBL] [Abstract][Full Text] [Related]
16. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. Wang X; Wang Y; Wang Y; Cheng J; Wang Y; Ha M J Biomed Sci; 2013 Jan; 20(1):5. PubMed ID: 23350714 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503 [TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170 [TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy. Yhim HY; Cho SH; Kim SY; Cho IS; Lee KT; Lee WS; Lee SI; Park MR; Park SG; Han HS; Choi YS; Chung IJ; Shim HJ; Lee NR; Song EK; Kim HS; Yim CY Oncol Rep; 2015 Jul; 34(1):155-64. PubMed ID: 25955097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]